Skip to main content

Table 1 Patient clinicopathological information

From: Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients

Sample ID

Treatment

Response

ER (%)

PgR (%)

HE R2 (IHC)

Ki67 (%)

07-9749

FEC → PH

non pCR

0

0

3+

NA

08-9679

FEC → PH

non pCR

100

80

3+

30

09-3788

FEC → PH

pCR

0

0

3+

10

09-5807

FEC → PH

pCR

80

30

3+

30

10-248

FEC → DH

pCR

60

70

3+

25

10-7977

FEC → PH

non pCR

30

0

3+

20

10-8712

FEC → PH

pCR

0

1

3+

40

11-577

FEC → PH

non pCR

5

0

3+

30

11-5192

FEC → PH

non pCR

10

30

3+

80

11-10011

FEC → PH

pCR

100

40

3+

22

12-2401

FEC → PH

pCR

10

0

3+

39.6

10-09897

FEC → PH

pCR

0

0

3+

25

10-06979

FEC → PH

non pCR

0

0

3+

10

  1. FEC, 5-fluorouracil epirubicin cyclophosphamide; P, paclitaxel; D, docetaxel; H, trastuzumab.